This antibody fragment which binds to CD1d can be used in treatment of conditions involving NKT (natural killer T) cell effector function.
Figure 1 Graphical Representation of results of assay demonstrating inhibition of tetramer binding by anti-CDld antibodies.
Figure 2 Graphical Representation of results of assay demonstrating inhibition of IL-2 release by anti-CDld antibodies.
Figure 3 Graphical Representation of results of assay demonstrating binding of anti-CDld antibodies to Primary peripheral blood mononuclear cells (PBMCs) by flow cytometry.
Figure 4 Graphical representation of results of a competition ELISA demonstrating that highly potent anti-CDld antibodies share a similar neutralizing epitope that is different to the epitope seen by lower-potency prior-art antibodies.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-418-VHH | Recombinant Anti-Human CD1d VHH Single Domain Antibody | IP, FC, ChiP, Neut | Llama VHH |
There are currently no Customer reviews or questions for TAB-1630CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.